BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9470840)

  • 1. Cisplatin pharmacokinetics in children with cancer.
    Peng B; English MW; Boddy AV; Price L; Wyllie R; Pearson AD; Tilby MJ; Newell DR
    Eur J Cancer; 1997 Oct; 33(11):1823-8. PubMed ID: 9470840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B; Nier M; Kern W; Hiddemann W; Pekrun A; Lakomek M
    Eur J Clin Pharmacol; 2001 Aug; 57(5):393-402. PubMed ID: 11599657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.
    Peng B; Tilby MJ; English MW; Price L; Pearson AD; Boddy AV; Newell DR
    Br J Cancer; 1997; 76(11):1466-73. PubMed ID: 9400943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
    van der Vijgh WJ; Elferink F; Vermorken JB; ten Bokkel Huinink WW; Klein I; Gall HE; Simonetti G; McVie JG; Pinedo HM
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):621-7. PubMed ID: 3383966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of carboplatin.
    Oguri S; Sakakibara T; Mase H; Shimizu T; Ishikawa K; Kimura K; Smyth RD
    J Clin Pharmacol; 1988 Mar; 28(3):208-15. PubMed ID: 3283185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors.
    Dominici C; Petrucci F; Caroli S; Alimonti A; Clerico A; Castello MA
    J Clin Oncol; 1989 Jan; 7(1):100-7. PubMed ID: 2909663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of carboplatin in children.
    Riccardi R; Riccardi A; Lasorella A; Di Rocco C; Carelli G; Tornesello A; Servidei T; Iavarone A; Mastrangelo R
    Cancer Chemother Pharmacol; 1994; 33(6):477-83. PubMed ID: 8137457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of high-dose cisplatin in children: pharmacokinetics of free and total platinum.
    Bues-Charbit M; Gentet JC; Bernard JL; Breant V; Cano JP; Raybaud C
    Eur J Cancer Clin Oncol; 1987 Nov; 23(11):1649-52. PubMed ID: 3428333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
    Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
    Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.
    Veal GJ; Dias C; Price L; Parry A; Errington J; Hale J; Pearson AD; Boddy AV; Newell DR; Tilby MJ
    Clin Cancer Res; 2001 Aug; 7(8):2205-12. PubMed ID: 11489793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
    Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
    Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum.
    Hanada K; Nishijima K; Ogata H; Atagi S; Kawahara M
    Jpn J Clin Oncol; 2001 May; 31(5):179-84. PubMed ID: 11450990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
    Bonetti A; Franceschi T; Apostoli P; Messori A; Sperotto L; Cetto GL; Molino A; Leone R
    Ther Drug Monit; 1995 Feb; 17(1):25-32. PubMed ID: 7725373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
    Nagai N; Ogata H
    Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. cis-Diamminedichloroplatinum(II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: a pharmacokinetic approach.
    Morazzoni F; Canevali C; Zucchetti M; Caroli S; Alimonti A; Petrucci F; Giudice G; Masoni E; Bedini AV
    J Cancer Res Clin Oncol; 1998 Jan; 124(1):37-43. PubMed ID: 9498833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions.
    Erdlenbruch B; Pekrum A; Roth C; Grunewald RW; Kern W; Lakomek M
    Pediatr Nephrol; 2001 Jul; 16(7):586-93. PubMed ID: 11465809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.